Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.49 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 2/20 | 0.45 |
| ▸ | BTK | Q06187 | 8/20 | 0.43 |
| ▸ | PAK4 | O96013 | 2/20 | 0.42 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30885318 | 1.00 | HRH4 (0.53) | HRH4MAP4K4DOT1LLRRK2JAK3 | |
| SCHEMBL27201417 | 0.83 | MAP4K4 (0.52) | HRH4MAP4K4DOT1LLRRK2JAK3 | |
| SCHEMBL27201410 | 0.81 | MAP4K4 (0.53) | HRH4MAP4K4LRRK2 | |
| SCHEMBL27201579 | 0.80 | MAP4K4 (0.53) | HRH4MAP4K4LRRK2BTK | |
| SCHEMBL30885255 | 0.80 | MAP4K4 (0.53) | HRH4MAP4K4LRRK2BTK | |
| SCHEMBL27201514 | 0.80 | MAP4K4 (0.51) | HRH4MAP4K4LRRK2 | |
| SCHEMBL30885232 | 0.78 | MAP4K4 (0.51) | HRH4MAP4K4LRRK2BTK | |
| SCHEMBL27201635 | 0.78 | MAP4K4 (0.51) | HRH4MAP4K4LRRK2BTK | |
| SCHEMBL30834277 | 0.77 | MAP4K4 (0.51) | HRH4MAP4K4LRRK2BTK | |
| SCHEMBL27201438 | 0.77 | MAP4K4 (0.51) | HRH4MAP4K4LRRK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | claimed |
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | GID4, MDM2, XIAP | HRH4 4074/4885MAP4K4 1878/4885DOT1L 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.